

## References

### I-9

1. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016. Accessed November 9, 2017.
2. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
3. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
4. Micromedex DrugDex Compendium® 2023. Imiglucerase.
5. Micromedex DrugDex Compendium® 2023. Velaglucerase Alfa.
6. Micromedex DrugDex Compendium® 2023. Taliglucerase alfa.
7. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Imiglucerase.
8. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Taliglucerase Alfa.
9. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Velaglucerase Alfa.
10. Stirnemann J, Belmatoug N, Camou F, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. *Int J Mol Sci*. 2017;18(2):441.
11. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. *Expert Rev Endocrinol Metab*. 2018;13(2):107-118.
12. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. *Mol Genet Metab* 2017;120(1-2);47-56.
13. Pastores GM, Hughes DA. Gaucher disease. *GeneReviews*. 2018;1-35.
14. Cerezyme (imiglucerase) for injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Revised 12/2022.
15. Eleyso (taliglucerase alfa) for injection, for intravenous use [package insert]. Pfizer Labs. New York, New York. Revised 08/2022.
16. VPRIV (velaglucerase alfa) for injection, for intravenous use [package insert]. Shire Human Genetic Therapies, Inc. Lexington, MA. Revised 09/2021
17. National Institute of Health. National Organization for Rare Disorders. Gaucher Disease. Last published: 2018.
18. Lau H, Belmatoug N, Deegan P, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. *Blood Cells Mol Dis*. 2018;68:226-231.
19. Weinreb NJ, Camelo JS Jr, Charrow J, et al. International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. *Mol Genet Metab*. 2021;132(2):100-111.

20. Imiglucerase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 21, 2017.
21. Taliglucerase alfa In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 22, 2017.
22. Velaglucerase alfa In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 22, 2017.